Breast Cancer News and Research

Latest Breast Cancer News and Research

Discovery of new genetic clues to breast cancer

Researchers at Cambridge University have identified five genetic clues for women who have a family history of breast cancer. The study brings up the number of common genetic variations linked to increased risk of breast cancer in women to 18. The study was published in Nature Genetics.

9 May 2010

Creator of California Tay-Sachs Disease Prevention Program among the honorees

A mere 40 years ago, parents didn't know they were carriers of the Tay-Sachs disease until after they'd given birth to a child with this fatal genetic disorder.

7 May 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.

7 May 2010

New research examines coping and appraisal of disease-related pain

Growing evidence suggests how individuals cope with and appraise disease-related pain, such as arthritis or cancer, is related not only to their experience with pain but also to their physical and psychological functioning, according to new research presented here today in a plenary session talk at the American Pain Society's annual scientific meeting.

7 May 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

A checklist to stay healthy at every age

Shantanu Nundy, MD, a second-year resident in internal medicine at the University of Chicago Medical Center may soon find out. Driven by his mother's health questions and the difficulty of providing simple, reliable answers, Nundy collected all of the "generally accepted truths" about preventing disease, organized them into checklists based on age, and persuaded the Johns Hopkins University Press to publish them as Stay Healthy at Every Age: What Your Doctor Wants you to Know.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

Cancer researchers at Princess Margaret Hospital have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

CU-Boulder develops inhalable vaccine for measles prevention

A team of researchers led by the University of Colorado at Boulder believe a dry powder, inhalable vaccine developed for measles prevention and slated for human clinical trials later this year in India will lead to other inhalable, inexpensive vaccines for illnesses ranging from tuberculosis to cervical cancer.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Whole body MRI helps physicians diagnose and treat breast cancer: Study

Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Watson Laboratories files raloxifene hydrochloride tablet ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

C. R. Bard reaches definitive agreement to acquire SenoRx

C. R. Bard, Inc. today announced that it has reached a definitive agreement to acquire SenoRx, Inc. (Nasdaq: SENO), for a purchase price of $11.00 per share in cash, totaling approximately $200 million, net of cash acquired.

6 May 2010

Survey reveals need for educating U.S. women about stroke symptoms

Although more than 425,000 women suffer from stroke each year, 55,000 more than men, a new survey showed that women may be dramatically underestimating their risk of this medical emergency, the third leading cause of death in the United States. Only 27 percent of women who were surveyed could name more than two of the six primary stroke symptoms. Moreover, seven out of 10 women who were surveyed said they are not aware they are more likely than men to have a stroke, and were not at all or only somewhat knowledgeable about risk factors.

5 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010